Patents by Inventor Michael Strerath

Michael Strerath has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150329629
    Abstract: Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNF?); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids.
    Type: Application
    Filed: April 24, 2015
    Publication date: November 19, 2015
    Inventors: Christian Votsmeier, Uwe Gritzan, Kornelia Kirchner, Michael Strerath, Kerstin Baral, Ulrich Haupts, Wayne M. Coco, Susanne Steinig, Andreas Scheidig, Klaus Pellengahr, Simone Brückner, Hanna Plittersdorf, Peter Scholz, Jan Tebbe
  • Publication number: 20150099298
    Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
    Type: Application
    Filed: May 8, 2013
    Publication date: April 9, 2015
    Inventors: Andreas Wilmen, Julia Straßburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jörißen, Asako Itakura, Philberta Leung, Erik Tucker
  • Publication number: 20140271660
    Abstract: This patent document relates to antibodies, antigen-binding antibody fragments (Fabs), and other protein scaffolds, directed against human antithrombin ? complexed with heparin and/or heparin-like structure (AT?H). These AT?H binding proteins can block the anti-coagulant activity of AT? to induce coagulation. Therapeutic uses of these antibodies and binders are described herein as are methods of panning and screening specific antibodies.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: BAYER HEALTHCARE LLC
    Inventors: YE JIN, JOHN E. MURPHY, TERRY HERMISTON, TIMOTHY MYLES, FRANK DITTMER, MICHAEL STRERATH, UWE GRITZAN
  • Publication number: 20140271661
    Abstract: This patent document relates to antibodies, antigen-binding antibody fragments (Fabs), and other protein scaffolds, directed against human antithrombin ? complexed with heparin and/or heparin-like structure (AT?H). These AT?H binding proteins can block the anti-coagulant activity of AT? to induce coagulation. Therapeutic uses of these antibodies and binders are described herein as are methods of panning and screening specific antibodies.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: Bayer HealthCare LLC
    Inventors: YE JIN, John E. Murphy, Terry Hermiston, Timothy Myler, Frank Dittmer, Michael Strerath, Uwe Gritzan
  • Publication number: 20130230886
    Abstract: Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNF?); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids.
    Type: Application
    Filed: March 13, 2013
    Publication date: September 5, 2013
    Inventors: Christian Votsmeier, Uwe Gritzan, Kornelia Kirchner, Michael Strerath, Kerstin Baral, Ulrich Haupts, Wayne M. Coco, Susanne Steinig, Andreas Scheidig, Klaus Pellengahr, Simone Brückner, Hanna Plittersdorf, Peter Scholz, Jan Tebbe
  • Patent number: 8399627
    Abstract: Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNF?); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids.
    Type: Grant
    Filed: December 24, 2008
    Date of Patent: March 19, 2013
    Assignee: Bayer Pharma AG
    Inventors: Christian Votsmeier, Uwe Gritzan, Kornelia Kirchner, Michael Strerath, Kerstin Baral, Ulrich Haupts, Wayne M. Coco, Susanne Steinig, Andreas Scheidig, Klaus Pellengahr, Simone Brückner, Hanna Plittersdorf, Peter Scholz, Jan Tebbe
  • Publication number: 20120237496
    Abstract: The present invention relates to polypeptides comprising protease variants of wild type human neprilysin having an altered specificity and/or activity. In particular the present invention relates to polypeptides comprising protease variants derived from human neprilysin having an increased specificity and/or activity against certain substrates, in particular against amyloid beta.
    Type: Application
    Filed: June 21, 2010
    Publication date: September 20, 2012
    Inventors: Joerg Birkenfeld, Andrea Eicker, Per-Ola Freskgard, Claudia Gotzberger-Schad, Joanna Grudzinska, Ulrich Haupts, Josi Innig, Christoph Mahlert, Andreas Scheidig, Michael Strerath, Jan Tebbe, Johan Per-Wallin, Nina Wobst, Carl Innes Webster, Lutz Jermutus
  • Publication number: 20100297700
    Abstract: Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNF?); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids.
    Type: Application
    Filed: December 24, 2008
    Publication date: November 25, 2010
    Inventors: Christian Votsmeier, Uwe Gritzan, Kornelia Kirchner, Michael Strerath, Kerstin Baral, Ulrich Haupts, Wayne Coco, Susanne Steinig, Andreas Scheidig, Klaus Pellengahr, Simone Brückner, Hanna Plittersdorf, Peter Scholz, Jan Tebbe